Translational research on prolyl oligopeptidase inhibitors: The long road ahead

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 7, 2011, Pages 977-981

  Lambeir, Anne Marie ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Alzheimer's disease; neurodegeneration; neuroinflammation; Parkinson's disease; prolyl oligopeptidase

Indexed keywords

PROLYL ENDOPEPTIDASE; PROLYL ENDOPEPTIDASE INHIBITOR;

ALZHEIMER DISEASE; DEGENERATIVE DISEASE; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; HUMAN; MENTAL DISEASE; NONHUMAN; PARKINSON DISEASE; PATENT; REVIEW;

ANIMALS; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; HUMANS; SERINE ENDOPEPTIDASES;

EID: 79959386446     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2011.587803     Document Type: Review

References (25)

1. Lopez A, Tarrago T, Giralt E. Low molecular weight inhibitors of Prolyl Oligopeptidase: a review of compounds patented from 2003 to 2010. Expert Opin Ther Pat 2011;21(7):1023-44
2. Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature 2002;417:292-5 (Pubitemid 34534711)
3. Morain P, Lestage P, De Nanteuil G, et al. S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies. CNS Drug Rev 2002;8:31-52 (Pubitemid 34651314)
4. Mannisto PT, Venalainen J, Jalkanen A, Garcia-Horsman JA. Prolyl oligopeptidase: a potential target for the treatment of cognitive disorders. Drug News Perspect 2007;20:293-305 (Pubitemid 47345221)
5. Bellemere G, Morain P, Vaudry H, Jegou S. Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. J Neurochem 2003;84:919-29 (Pubitemid 36330646)
6. Garcia-Horsman JA. Prolyl oligopeptidase in brain function and dysfunction. CNS Neurol Disord Drug Targets 2011;10:296
7. Harwood AJ. Prolyl oligopeptidase, inositol phosphate signalling and lithium sensitivity. CNS Neurol Disord Drug Targets 2011;10:333-9
8. Lambeir AM. Interaction of Prolyl Oligopeptidase with alpha-Synuclein. CNS Neurol Disord Drug Targets 2011;10:349-54
9. Morawski M, Schulz I, Zeitschel U, et al. Role of prolyl oligopeptidase in intracellular transport and protein secretion. CNS Neurol Disord Drug Targets 2011;10:327-32
10. Peltonen I, Myohanen TT, Mannisto PT. Association of prolyl oligopeptidase with conventional neurotransmitters in the brain. CNS Neurol Disord Drug Targets 2011;10:311-18
11. Penttinen A, Tenorio-Laranga J, Siikanen A, et al. Prolyl oligopeptidase: a rising star on the stage of neuroinflammation research. CNS Neurol Disord Drug Targets 2011;10:340-8
12. Peltonen I, Jalkanen AJ, Sinerva V, et al. Different effects of scopolamine and inhibition of prolyl oligopeptidase on mnemonic and motility functions of young and 8- to 9-month-old rats in the radial-arm maze. Basic Clin Pharmacol Toxicol 2010;106:280-7
13. Rossner S, Schulz I, Zeitschel U, et al. Brain prolyl endopeptidase expression in aging, APP transgenic mice and Alzheimer's disease. Neurochem Res 2005;30:695-702 (Pubitemid 41413928)
14. Laitinen KS, van Groen T, Tanila H, et al. Brain prolyl oligopeptidase activity is associated with neuronal damage rather than beta-amyloid accumulation. Neuroreport 2001;12:3309-12 (Pubitemid 33010662)
15. Sleegers K, Lambert J-C, Bertram L, et al. The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet 2009;26:84-93
16. Bekris LM, Mata IF, Zabetian CP. The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 2010;23:228-42
17. Saito M, Hashimoto M, Kawaguchi N, et al. Synthesis and inhibitory activity of acyl-peptidyl-prolinalderivatives toward post-proline cleaving enzyme as nootropic agents. J Enzyme Inhib 1990;3:163-78 (Pubitemid 20080687)
18. Collins PJ, McMahon G, O'Brien P, O'Connor B. Purification, identification and characterisation of seprase from bovine serum. Int J Biochem Cell Biol 2004;36:2320-33 (Pubitemid 39094452)
19. Cunningham DF, O'Connor B. Identification and initial characterisation of a N-benzyloxycarbonyl-prolyl-prolinal (Z-Pro-prolinal)-insensitive 7-(N-benzyloxycarbonyl-glycyl-prolylamido)- 4-methylcoumarin (Z-Gly-Pro-NH-Mec)-hydrolysing peptidase in bovine serum. Eur J Biochem 1997;244:900-3 (Pubitemid 27130529)
20. Lawandi J, Gerber-Lemaire S, Juillerat-Jeanneret L, Moitessier N. Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. J Med Chem 2010;53:3423-38
21. Tenorio-Laranga J, Valero ML, Mannisto PT, et al. Combination of snap freezing, differential pH two-dimensional reverse-phase high-performance liquid chromatography, and iTRAQ technology for the peptidomic analysis of the effect of prolyl oligopeptidase inhibition in the rat brain. Anal Biochem 2009;393:80-7
22. Nolte WM, Tagore DM, Lane WS, Saghatelian A. Peptidomics of prolyl endopeptidase in the central nervous system. Biochemistry 2009;48:11971-81
23. Warden CH, Fisler JS, Espinal G, et al. Maternal influence of prolyl endopeptidase on fat mass of adult progeny. Int J Obes (Lond) 2009;33:1013-22
24. Perroud B, Alvarado RJ, Espinal GM, et al. In vivo multiplex quantitative analysis of 3 forms of alpha melanocyte stimulating hormone in pituitary of prolyl endopeptidase deficient mice. Mol Brain 2009;2:14
25. Di Daniel E, Glover CP, Grot E, et al. Prolyl oligopeptidase binds to GAP-43 and functions without its peptidase activity. Mol Cell Neurosci 2009;41:373-82.